MedTrace Logo

Development of a Molecular Diagnostic Tool for Endometrial Cancer.

NCT06192017 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1950

Last updated 2025-08-28

No results posted yet for this study

Summary

WomEC is an in vitro diagnostic test for Endometrial Cancer (EC) based on the detection of the expression level of a combination of 5 proteins in the soluble fraction of a pipelle biopsy specimen. The aim of the study consists in validating WomEC's ELISA test, creating and freezing an algorithm to rule out EC in post-menopausal women with abnormal uterine bleeding (AUB).

Conditions

  • Endometrium Cancer

Interventions

DIAGNOSTIC_TEST

WomEC

The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.

Sponsors & Collaborators

  • Hospital Vall d'Hebron

    collaborator OTHER

  • MiMARK Diagnostics, S.L.

    lead INDUSTRY

Principal Investigators

  • Antonio Gil-Moreno, MD, PhD · Hospital Universitari Campus Vall d'Hebron

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-18
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06192017 on ClinicalTrials.gov